UK markets closed

BNTX Jan 2025 130.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
39.290.00 (0.00%)
As of 10:38AM EDT. Market open.
Full screen
Previous close39.29
Open39.36
Bid39.10
Ask40.20
Strike130.00
Expiry date2025-01-17
Day's range39.29 - 39.36
Contract rangeN/A
Volume4
Open interest349
  • Bloomberg

    BioNTech Cancer Drug Licensed From MediLink Faces FDA Delay

    (Bloomberg) -- The Food and Drug Administration delayed a breast- and lung-cancer trial of an experimental treatment that BioNTech SE licensed from Chinese biotech MediLink Therapeutics Ltd., citing safety concerns.Most Read from BloombergFlesh-Eating Bacteria That Can Kill in Two Days Spreads in JapanHow the US Mopped Up a Third of Global Capital Flows Since CovidThese Are the World’s Most Expensive Cities for Expats in 2024Hedge Funds’ Secret Weapon to Fight the SEC Lives in TexasS&P 500 Set f

  • Yahoo Finance Video

    FDA considers updating COVID boosters, Novavax stock reacts

    The US Food and Drug Administration (FDA) is set to vote on recommendations for updated COVID-19 booster shots as the KP.2 variant strain begins to spread across the US. Yahoo Finance Health Reporter Anjalee Khemlani joins Market Domination to discuss the impact this is having on vaccine makers, particularly Novavax (NVAX), whose stock has shot up in Monday's session. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.

  • Globe Newswire

    Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

    Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small cell lung cancer treated with a combination of acasunlimab and pembrolizumab every six weeksData from this ongoing Phase 2 study to inform the planned pivotal Phase 3 trial, which is expected to start before the end of 2024 COPENHAGEN, Denmark, and MAINZ, Germany, June 1, 2024 — Genmab A/S (